Startseite>>Signaling Pathways>> Metabolism>> PDE>>Dyphylline

Dyphylline (Synonyms: 7-(2,3-Dihydroxypropyl)theophylline, Dilor, Diprophylline, Lufyllin, Neothyllin, NSC 14305, NSC 40844)

Katalog-Nr.GC13652

An adenosine receptor antagonist and phosphodiesterase inhibitor

Products are for research use only. Not for human use. We do not sell to patients.

Dyphylline Chemische Struktur

Cas No.: 479-18-5

Größe Preis Lagerbestand Menge
10mM (in 1mL DMSO)
38,00 $
Auf Lager
50mg
46,00 $
Auf Lager

Tel:(909) 407-4943 Email: sales@glpbio.com

Kundenbewertungen

Basiert auf Kundenrezensionen.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Dyphylline acts as an adenosine receptor antagonist and phosphodiesterase inhibitor, which is used in the treatment of respiratory disorders.Target: Adenosine Receptor; PDEDyphylline (trade names Dilor, Lufyllin), also known as diprophylline, is a xanthine derivative with bronchodilator and vasodilator effects. It is used in the treatment of respiratory disorders like asthma, cardiac dyspnea, and bronchitis. It acts as an adenosine receptor antagonist and phosphodiesterase inhibitor.

References:
[1]. Schwabe U, et al. Xanthine derivatives as antagonists at A1 and A2 adenosine receptors. Naunyn Schmiedebergs Arch Pharmacol. 1985 Sep;330(3):212-21.
[2]. Iancu L, et al. Trials with xanthine derivatives in systemic treatment of psoriasis. Dermatologica. 1979;159(1):55-61.

Bewertungen

Review for Dyphylline

Average Rating: 5 ★★★★★ (Based on Reviews and 30 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Dyphylline

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.